[Role of interleukin-1 in osteoarthritis].

W. B. van den Berg

Abstract:

What problem does this paper attempt to address?

Clinical Performance of Enzyme Linked Immunosorbent Assay Detecting Serum Antibodies Against Double-stranded DNA in Diagnosis of Systemic Lupus Erythematosus

史晓敏,冯珍如,隋宝环,阎振林,董宁

DOI: https://doi.org/10.3969/j.issn.1007-9572.2011.02.017

2011-01-01

Chinese General Practice

Abstract:Objective To estimate the clinical performance of enzyme linked immunosorbent assay(ELISA) kits(Anti-dsDNA-NcX ELISA) detecting serum antibodies against double-stranded DNA(dsDNA) in the diagnosis of Systemic lupus erythematosus(SLE).Methods A performance evaluation was carried out on Anti-dsDNA-NcX ELISA kits.Indirect immunofluorescence(IIF) and ELISA(a total of 3 kits) were used to detect serum anti-dsDNA antibodies in 30 healthy subjects,27 non-SLE patients with autoimmune disease and 92 SLE patients.Taking SLE diagnosis as gold standard,the diagnosis performance of Anti-dsDNA-NcX ELISA in SLE was evaluated.Results Anti-dsDNA-NcX ELISA kits were up to the laboratory testing indexes,with the lowest detection limit of 2.8 U/ml,linear correlation coefficient of 0.998,within-run precision of CV6%,between-run precision of CV10%.Hemolysis,lipemia and jaundice did not interfere with the test results,having no cross reaction with serum of patients with non-SLE autoimmune diseases such as rheumatoid arthritis,Sjogren′s syndrome,etc.The anti-dsDNA antibody P97.5 was 67.0 U/ml in healthy subjects.The positive rate of 2 kinds of ELISA reagents(60.9%) was higher than that of IIF(20.6%),the difference was significant(P0.05),among which the accuracy of anti-dsDNA-NcX ELISA kits significantly higher than that of AESKULISA dsDNA-Check ELISA kits(The areas under the curve were 0.90,0.68,respectively) in diagnosis of lupus nephritis(P0.05).Taking 108U/ml of anti-dsDNA antibody as diagnosis cut-off line,the specificity of Anti-dsDNA-NcX ELISA kits was 98.2%,positive predictive value was 96.6% in diagnosis of lupus nephritis.Conclusion Anti-dsDNA-NcX ELISA kits,having good detection performance and improving specificity and positive predictive value without reducing sensitivity,are beneficial additions for IIF.Its reagent can be used for clinical diagnosis of SLE.
Clinical Evaluation of A New Quantitative Enzyme-Linked Immunosorbent Assay for Anti-Dsdna Antibodies Measured in Patients with Systemic Lupus Erythematosus

Liyan Cui,Jie Zhang,Xiaozhou Hu,Wenjing Zhang,Jie Ding

DOI: https://doi.org/10.1309/lmljnssxx4pc37pl

IF: 1.865

2010-01-01

Laboratory Medicine

Abstract:Background The measurement of autoantibodies specific for double stranded DNA (anti dsDNA) is a useful tool for the diagnosis and prognosis of systemic lupus erythematosus (SLE) A quantitative enzyme linked immunosorbent assay (ELISA) for anti dsDNA antibodies has recently become available for the determination of anti dsDNA antibodies The aim of this study was to evaluate the clinical performance characteristics of this assay in patients with inactive or active SLEMethods Serum samples from patients with inactive (n=65) or active (n=112) SLE were tested for anti dsDNA autoantibodies using 2 methods from Euroimmun AG (Lubeck, Germany) a new ELISA anti dsDNA assay and the currently available Crithidia luciliae indirect immunofluorescent test (CLIFT) In addition, the levels of the complement components C3 and C4 biological markers associated with SLE disease activity were measured by nephelometry in the sera from all patientsResults The sensitivity and specificity of the anti dsDNA ELISA assay for discriminating between patients with inactive or active SLE were 93 54% and 67 69% respectively Among all patients (n=177) there was a weak concordance (kappa=0 264) between anti dsDNA results by the ELISA and CLIFT assay However a significant inverse correlation was found with complement components levels In addition, area under the curve (AUC) values for anti dsDNA as well as C3 and C4 assays decreased in the following order 0 901 (ELISA for anti dsDNA autoantibodies)>0 734 (C3)>0 723 (C4)>0 650 (CLIFT for anti dsDNA autoantibodies)Conclusions Our results show the ELISA for anti dsDNA autoantibodies is significantly more sensitive and specific than any of the other assays we evaluated for discriminating between patients with inactive or active SLE Moreover, the inverse correlation between ELISA anti dsDNA autoantibody and complement levels suggests that anti dsDNA results by the Euroimmun ELISA may be promising for monitoring disease activity in patients with SLE
Two tests to detect anti-double stranded DNA antibodies in the diagnostic value of systemic lupus erythematosus

Xiao-min SHI,Zhen-lin YAN,Bao-huan SUI,Zhen-ru FENG

DOI: https://doi.org/10.3760/cma.j.issn.1009-9158.2012.08.019

2012-01-01

Abstract:Objective To investigate the concurrent application value of indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA) in systemic lupus erythematosus (SLE).Methods A retrospective study.All patients who took anti-double stranded DNA (dsDNA) antibody test from June 1 2011 to September 30 2011 in our department were recruited in this study.The patients' anti-dsDNA antibody results and clinical diagnosis were collected and analyzed retrospectively.The consistence,sensitivity and specificity of IIF and ELISA tests were calculated and the consistence was compared by Kappa test.Results The positive rates of detecting anti-dsDNA antibodies by ELISA and IIF tests were 16.3％ and 13.1％ respectively.The consistency between these two tests was 90.8％,and showed good correlation by Kappa test (Kappa =0.641,P ＜ 0.05 ).Of 9.2％ of inconsistent results between IIF andi ELISA,most cases ( 6.2％ ) were ELISA positive and IIF negative.Taking the clinical diagnosis of lupus as a golden standard,the accuracy of IIF and ELISA was 84.8％ and 84.4％ respectively and the difference was no significant (x2 =0.25,P ＞ 0.05 ).The sensitivity and specificity for diagnosing lupus by IIF were 46.1％ and 99.2％,and 51.3％ and 96.7％ by ELISA.Conclusions Our results suggested that anti-dsDNA antibodies in samples should be detected by both ELISA and IIF tests simultaneously.If ELISA was used first and the positive samples were further tested by IIF,at least 3％ of ELISA negative and IIF positive samples would be misdiagnosed as anti-dsDNA antibodies negative.IIF negative and ELISA positive samples should be further analyzed the affinity of anti-dsDNA antibodies in order to help the diagnosis and evaluation of SLE.
An assessment on diagnostic efficacy of different methods in combination for the detection of anti-dsDNA antibody in SLE patients

TIANYe,Yuncong ZHANG,Zhenru FENG,YANHuiping,Haiping ZHANG,Pei LI,Fangfang ZHENG,Qiuyan NIE,Qing LIU,X WANG,TANYanguo,Guojun ZHANG

DOI: https://doi.org/10.3969/j.issn.1672-9455.2016.19.001

2016-01-01

Abstract:Objective To investigate the prevalence of anti-dsDNA antibody in several autoimmune diseases ,and evaluate the di-agnostic efficacy of ELISA and indirect immunofluorescence (IIF) techniques for the detection of anti-dsDNA antibody in SLE pa-tients .Methods Using commercially available kits based on ELISA (ELISA1 ,ELISA2) and IIF techniques simultaneously ,serum anti-dsDNA antibody was determined in 300 SLE patients ,495 non-SLE autoimmune disease patients ,and 300 health controls .The efficacy of anti-dsDNA antibody determined by one method or combined methods for the diagnostic of SLE patients was further e-valuated .Results The positive rates of anti-dsDNA antibody in SLE patients detected by ELISA1 ,ELISA2 and IIF kit were 42 .3% ,35 .3% and 38 .0% respectively .An utmost prevalence in the non-SLE patients and health controls were 1 .2% and 0 .3%respectively .In SLE patients ,Kappa values of ELISA1 and ELISA2 ,ELISA1 and IIF ,ELISA2 and IIF were 0 .672 ,0 .398 ,0 .512 re-spectively(P< 0 .05) .A significant difference was only observed between ELISA1 and ELISA2(P= 0 .003) .The area under the re-ceiver operating curve (AUC)of ELISA1 ,ELISA2 and IIF were 0 .708 ,0 .672 and 0 .687 respectively ,based on the result obtained from individual method .when ELISA1 kit and IIF kit were used in combination ,the highest positive rate and AUC were 54 .7% and 0 .764 in SLE patients .When three kinds of kits were used in combination ,the highest positive rate and AUC were 57 .7% and 0 .781 .Conclusion Using ELISA and IIF in combination to detect anti-dsDNA antibody could greatly improve the efficacy for the diagnosis of SLE .
Comparisons of Anti-dsDNA Antibody Detection Methods by Chemiluminescent Immunoassay and Enzyme-Linked Immunosorbent Assay in Systemic Lupus Erythematosus

Huang-Chen Chang,Yen-Ching Wu,Jun-Peng Chen,Yi-Da Wu,Wen-Nan Huang,Yi-Hsing Chen,Yi-Ming Chen

DOI: https://doi.org/10.3390/diagnostics11111940

IF: 3.6

2021-10-20

Diagnostics

Abstract:This study aimed to compare the test results of anti-double-stranded DNA (anti-dsDNA) antibodies obtained using chemiluminescent immunoassay (CIA) and enzyme-linked immunosorbent assay (ELISA), and investigate predictors of inconsistent results. This retrospective study included 502 patients who underwent CIA and ELISA to determine their anti-dsDNA antibody values within a year. We compared the diagnostic power for SLE, disease activity, and predictive power for lupus nephritis (LN). A multivariate analysis was performed to determine the predictors of inconsistencies. CIA and ELISA were moderately correlated in terms of their consistency (Cronbach’s α = 0.571), and yielded comparably favorable results in terms of SLE diagnostic power and SLE disease activity. However, if the patient had LN, CIA displayed higher predictive power than ELISA (0.620 vs. 0.555, p = 0.026). Compared with the CIA/ELISA double-positive group, the inconsistent group had lower anti-C1q circulating immune complexes (CIC) antibody values (OR: 0.42, 95% CI: 0.18–0.94, p = 0.036), and lower SLEDAI scores (≥4) (OR: 0.33, 95% CI: 0.14–0.79, p = 0.013). Anti-dsDNA antibody detection with CIA exhibited higher predictability for diagnosing LN than did ELISA. In the event of inconsistencies between anti-dsDNA methods, SLE disease activity and CIC test values should be considered simultaneously.

medicine, general & internal
Comparative analysis of contemporary anti-double stranded DNA antibody assays for systemic lupus erythematosus

Claus-Juergen Bauer,Pantelis Karakostas,Nadine Weber,Charlotte Behning,Birgit Stoffel-Wagner,Peter Brossart,Ramona Dolscheid-Pommerich,Valentin Sebastian Schäfer

DOI: https://doi.org/10.3389/fimmu.2023.1305865

IF: 7.3

2023-12-07

Frontiers in Immunology

Abstract:Objective Elevated double-stranded DNA (dsDNA) antibody levels in blood serum are considered a disease-specific marker in systemic lupus erythematosus (SLE), correlate with disease activity and the incidence of lupus nephritis, and can be detected in up to 86% of all SLE cases. Despite the high clinical relevance, the variety of dsDNA antibody testing methods with heterogenous performance in clinical use remains challenging. This study is the first to prospectively investigate the performance of two of today’s most commonly applied anti-dsDNA testing methods head-to-head under real-world conditions, as well as their correlation with other clinical and serological disease parameters in SLE patients. Methods In this prospective study, all SLE patients undergoing treatment at the Department of Rheumatology at the University Hospital Bonn within a 13-months period (n=41) and control patients without connective-tissue disease (n=51) were consecutively enrolled and examined. For all study participants’ serum samples both anti-dsDNA-NcX enzyme-linked immunoassay testing EUROIMMUN, Luebeck, Germany) and the fluorescence immunoassay ELiA dsDNA (Thermo Fisher Scientific, Waltham, USA) were performed. In addition, demographic data, further laboratory values and disease activity parameters were recorded. Clinical disease activity was assessed by SLEDAI-2K. Results Both assays showed high specificity (anti-dsDNA-NcX ELISA: 0.9, ELiA dsDNA: 0.959), but there were notable differences in sensitivity (anti-dsDNA-NcX ELISA: 0.51, ELiA dsDNA: 0.38). Pearsons’s correlation yielded a positive correlation between anti-dsDNA concentrations and CRP concentrations for the anti-dsDNA-NcX ELISA (R=0.22; p=0.038) and a mild-to-moderate inverse correlation between concentrations of anti-dsDNA and complement C4 for the ELiA dsDNA test (R=-0.22; p=0.045) when SLE and control patients were considered together. Other than, no significant correlation between anti-dsDNA concentrations and clinical or laboratory findings was found for either test procedure. Conclusion Both anti-dsDNA antibody assays represent reliable examination methods with high specificity for the diagnosis of SLE that fulfill EULAR/ACR requirements. However, the anti-dsDNA-NcX ELISA showed superior sensitivity and significant correlation with disease activity (as measured by CRP concentrations).

immunology
The correlation between the avidity or level of serum anti-dsDNA antibody with SLE disease progression and their influence on the performance of different detection techniques

Ye TIAN,Yuncong ZHANG,Zhenru FENG,Huiping YAN,Yan ZHANG,Haiping ZHANG,Pei LI,Fangfang ZHENG,Qiuyan NIE,Qing LIU,Xiaoning WANG,Guojun ZHANG,Yanguo TAN

DOI: https://doi.org/10.3969/j.issn.1672-9455.2018.02.002

2018-01-01

Abstract:Objective To investigate the connection between the avidity or level of anti-dsDNA antibody with the progression of systemic lupus erythematosus (SLE) ,and their influence on the performance of two widely used techniques (ELISA and IIF ) .Methods Using commercially available kits based on ELISA and IIF techniques simultaneously ,serum anti-dsDNA antibody was determined from 300 patients with SLE ,495 patients with non-SLE autoimmune disease ,and 300 health controls (HCs) .Positive samples by ELISA were further determined for anti-dsDNA antibody avidity index using urea based ELISA kits .Results (1)the level and avidity index of anti-dsDNA antibody were significantly and insignificantly higher in SLE than non-SLE patients[antibody level :285 .8(164 .5-463 .3) IU/mL vs .172 .9(135 .3-200 .1) IU/mL ,P=0 .038 ;antibody avidity index :32 .3(19 .2 -50 .7)vs .15 .5(9 .5-49 .8) ,P=0 .169] ,and significantly correlated with SLEDAI scores ,respectively (P=0 .000 ,0 .002) .(2)For samples whose anti-dsDNA antibody were positive by both ELISA and IIF ,their anti-dsDNA antibody levels and avidity indices were significantly higher than those sole-ly positive by ELSIA(P<0 .05).Conclusion The closely correlation of anti-dsDNA level and avidity index with SLE disease progression ,signifies that antibody amount and avidity might have been involved in disease development ,and could also be used to monitor disease progression .For the determination of anti-dsDNA anti-body ,IIF was more likely to detect antibodies of relatively higher avidity ,in comparison with ELISA .
Anti-Double-Stranded DNA Isotypes and Anti-C1q Antibody Improve the Diagnostic Specificity of Systemic Lupus Erythematosus

Yu Jia,Lingling Zhao,Chunyan Wang,Jin Shang,Yi Miao,Yangyang Dong,Zhanzheng Zhao

DOI: https://doi.org/10.1155/2018/4528547

2018-09-27

Disease Markers

Abstract:Objectives . We aimed to evaluate the value of immunoglobulin (Ig) G, IgM, and IgA isotypes of anti-double-stranded DNA (anti-dsDNA) and anti-C1q antibody in diagnosing systemic lupus erythematosus (SLE) patients and elucidate their association with disease activity and lupus nephritis. Methods . Blood samples were obtained from 96 SLE patients, 62 other autoimmune disease patients, and 60 healthy blood donors. Anti-dsDNA IgG, IgM, and IgA isotypes and anti-C1q antibody were measured by enzyme-linked immunosorbent assay. Disease activity of SLE patients was assessed according to the SLE Disease Activity Index score. Results . When specificity was greater than 90%, the sensitivity of anti-dsDNA IgG, IgM, and IgA isotypes and anti-C1q antibody in diagnosing SLE was 75%, 45%, 33%, and 49%, respectively. The prevalence of anti-dsDNA IgG ( p = 0.002 ), anti-dsDNA IgA ( p = 0.028 ), and anti-C1q antibody ( p = 0.000 ) in active cases was significantly higher than those in inactive ones. In addition, the presence of anti-C1q antibody was associated with renal involvement ( p = 0.032 ). Anti-dsDNA IgM showed no significant association with disease activity, but it was inversely linked with lupus nephritis ( p = 0.005 ). When anti-dsDNA IgG and IgA and anti-C1q were combined to evaluate SLE disease activity, the specificity reached the highest level (90%). When anti-C1q positive was accompanied by anti-dsDNA IgM negative, the specificity of diagnosing lupus nephritis was up to 96%. Conclusions . This study demonstrated the role of anti-dsDNA IgG, IgM, and IgA isotypes and anti-C1q antibody alone or combination in diagnosing SLE. Anti-dsDNA IgG and IgA and anti-C1q were shown to be associated with disease activity, while anti-dsDNA IgM and anti-C1q were associated with lupus nephritis. When the related antibodies were combined, the diagnostic specificity was significantly higher.

genetics & heredity,pathology,medicine, research & experimental,biotechnology & applied microbiology
Long Non-Coding RNAs in Systemic Lupus Erythematosus: New Insights into Disease Pathogenesis and Diagnosis.

Xin Chen,Qi Cheng,Huaxiang Wu,Yan Du

DOI: https://doi.org/10.1111/sji.13167

2022-01-01

Scandinavian Journal of Immunology

Abstract:Systemic lupus erythematosus (SLE) is a remarkable heterogeneous autoimmune disease that is sometimes hard to diagnose at the early stage and can lead to premature mortality. Long non-coding RNAs (lncRNAs) are a class of non-protein-coding RNAs greater than 200 nucleotides in length that can regulate gene expression in various human diseases, including SLE. Peripheral blood samples and renal tissue samples from SLE patients were used for study. Abnormally expressed lncRNAs in SLE have been shown to influence several signalling pathways, including the IFN-I, MAPK and WNT pathways. This can affect cellular phenotypes like cell activation, differentiation skewing, cytokine production and cell apoptosis. Many of the reported lncRNAs may be useful for diagnosing, evaluating progression and predicting potential organ damage in SLE patients. While numerous lncRNAs play important roles in SLE, more basic and clinical studies are warranted to clarify the function of these regulatory molecules and determine their diagnostic value.
Values of qualitative assays for anti-ds-DNA and anti-nucleosome antibodies in diagnosis of systemic lupus erythematosus

Na LI,Ning KONG,He-jian ZOU,Wei-guo WAN

DOI: https://doi.org/10.12025/j.issn.1008-6358.2018.20170355

2018-01-01

Abstract:Objective:To assess the diagnostic value of immunoblot assay for anti-double stranded DNA (ds-DNA) antibodies and anti-nucleosome antibodies (ANuA),and crithidia luciliae based indirect immunofluorescence for anti-ds-DNA antibodies in systemic lupus erythematosus (SLE) patients.Methods:The levels of anti-ds-DNA antibodies and ANuA in sera of 166 patients in active stage of SLE (including initial and recurrent patients) were detected by irnmunoblotting,crithidia luciliae immunofluorescence and enzyme-linked immunosorbent assay (ELISA).The values of qualitative detections for anti-dsDNA antibodies and ANuA in diagnosing SLE were evaluated taking ELISA as standard.Results:The positive coincident rate of immunoblotting for anti-ds-DNA antibodies and ANuA was 73.33％ and 66.28％,respectively.The positive coincident rate of crithidia luciliae immunofluorescence test for anti-ds-DNA antibodies was 68.57％.The positive coincident rates of immunoblotting and indirect immunofluorescent assay were both decreased with titers of anti-ds-DNA antibodies and ANuA (P＜0.05).Conclusions:The positive rates in diagnosis of SLE are not ideal using qualitative assays for ds-DNA antibody and ANuA,therefore,qualitative assay is recommended to be applied based on ELISA.
DNA-associated Autoantibodies to Cell Membrane for Rapid Detection of Systemic Lupus Erythematosus

陈适,贾汝林,韩蕾,穆荣,贾园,马本良,栗占国

DOI: https://doi.org/10.3760/j:issn:1007-7480.2001.04.006

2001-01-01

Abstract:Objective To evaluate the expression of autoantibodies to cell membrane associated with DNA (mDNA) in systemic lupus erythematosus (SLE).The specificity of these antibodies differs from antibodies to double stranded DNA.Method Using indirect immunofluorescence,serum samples were detected giving a characteristic pattern of peripheral membrane fluorescence on cultured HL60.Results This pattern was observed in 81 of 90 serum samplas of SLE patients,but absent in the serum samples of 35 rheumatoid arthritis,31 ankylosing spondylarthritis and 42 blood donors.In 20 Sjgren syndrome′s patients only one showed a positive test.Conclusion This novel rapid immunofluorescence method may serve as an identification test of SLE patients.Due to the sensitivity (90%) and specificity (98 8%),it is better than the other diagnostic tests such as the detection of antibodies to dsDNA and Sm.
The role of cyclic GMP-AMP synthase and Interferon-I-inducible protein 16 as candidatebiomarkers of systemic lupus erythematosus

Qiang Fu,Qiuying He,Qian Dong,Jinye Xie,Yiyun Geng,Hui Han,Yanhua Huang,Jianqiang Lu,Zhijie Zeng,Weijia Wang,Kang Chen,Xiaoxia Zhan

DOI: https://doi.org/10.1016/j.cca.2021.11.003

IF: 6.314

2022-01-01

Clinica Chimica Acta

Abstract:BACKGROUND: Diverse clinical and serological manifestations of systemic lupus erythematosus (SLE) compromise its diagnosis and treatment. A more reliable biomarker for SLE, which can play a critical role in either diagnosis, monitoring the disease progress or evaluating the response to treatment for individualized therapeutic, is necessary. DNA sensor is an important mediator of inflammation in systemic autoimmune diseases. However, the potential role for DNA sensor as disease activity biomarkers for SLE remained obscure. We detected the aberrant activation of DNA sensors and the corresponding IFN-β response in SLE patients, and to evaluate their potential role as disease biomarkers for SLE.METHODS: We quantified the expressions of IFN-I and DNA sensor, such as cGAS, IFI16, DDX41, DAI and their down-stream adaptor STING in PBMC derived from patients with SLE (n = 100), healthy controls (HCs) (n = 62) by real-time PCR. The relationships between the expression of cGAS or IFI16 and clinical features in SLE patients were investigated. ROC curve analysis was performed to examine the predictive value of cGAS and IFI16 in SLE diagnosis, disease activity monitoring, specific organ manifestation and therapeutic response. RNA interference-mediated depletion of IFI16 or cGAS was conducted to evaluate their impact on IFN-I response.RESULTS: The expressions of cGAS and IFI16 were significantly higher in PBMC from SLE patients, closely correlated with the SLEDAI scores and high anti-dsDNA antibody titers. While the AUC for cGAS (0.767) was less than that of IFI16 and IFN-β, the AUC for IFI16 (0.856) and IFN-β (0.856) were similar. Expression of cGAS and IFI16 combine with IFN-β in PBMC showed high sensitivity (89.2%) and specificity (89.1%) for discrimination between mild and moderate/severe disease activity in SLE. Higher expression of IFI16 was association with ocular disorder in SLE patients. Neither IFI16 nor cGAS was a reliable indicator of therapeutic response. RNA interference-mediated depletion of IFI16 or cGAS prevented active SLE serum-induced upregulating in both IFN-α and IFN-β.CONCLUSIONS: High expression levels of cGAS and IFI16 in PBMC from SLE patients correlated strongly with disease activity. Both cGAS and IFI16 mediated signaling pathway were account for the robust production of IFN-β. Expression of cGAS and IFI16 combined with IFN-β in PBMC might serve as potential biomarkers for early diagnosis and monitoring disease activity in SLE.

medical laboratory technology
Correlation of systemic lupus erythematosus clinical phenotypes with anti-double-stranded DNA antibodies and performance comparison of 4 commercial determination kits

Rui SONG,Ping YE,Chaohui WEI,Xiaoxiang CHEN,Jiucun WANG

DOI: https://doi.org/10.3969/j.issn.1673-8640.2017.04.016

IF: 1.865

2017-01-01

Laboratory Medicine

Abstract:Objective To compare the performance of 4 commercial determination kits for anti-double-stranded DNA (dsDNA)antibodies,to analyze the correlation of 15 typical systemic lupus erythematosus (SLE)clinical phenotypes with anti-dsDNA antibodies,and to provide a reference for the diagnosis and monitoring of SLE. Methods A total of 229 SLE patients were enrolled,and 112 patients with other connective tissue diseases were enrolled. Their serum samples were collected. There were 10 typical SLE clinical phenotypes and 5 parameters. All SLE patients were evaluated according to SLE disease activity index (SLEDAI). The levels of anti-dsDNA antibodies were determined by 4 commercial determination kits [kit A using indirect immunofluorescence assay(IFA),kit B and kit C using enzyme-linked immunosorbent assay(ELISA)and kit D using radioimmunoassay]. The performance of the 4 commercial determination kits was evaluated. The correlation of typical SLE clinical phenotypes and parameters with anti-dsDNA antibodies was analyzed. Results The results of 4 commercial determination kits had statisticalsignificance(P<0.01). Kit C had the highest Youden's index,its Youden's index was higher than those of kit B and kit D,and that of kit A was the lowest. The results of kit B,C and D had correlations with SLEDAI (r= 0.482, 0.512 and 0.685,P<0.01). For 10 typical SLE clinical phenotypes and 5 parameters,anti-dsDNA antibodies were correlated positively with increasing anti-nucleosome antibody and decreasing complement (P<0.01). The results of positive anti-nuclear antibodies (P<0.05),nephropathy (P<0.05),leukopenia (P<0.05) and malar rash(P<0.05) in 2 kits were positively correlated with anti-dsDNA antibodies. The other 8 typical SLE clinical phenotypes,including thrombocytopenia and peripheral arthritis,showed no correlation with anti-dsDNA antibodies. Conclusions The performance of 4 commercial determination kits is different. Kit C is adapted to screen SLE,and kit D is suitable for monitoring the activity of SLE. Nephropathy,malar rash,anti-nucleosome antibody, anti-nuclear antibody,decreasing complement and leukopenia are correlated with anti-dsDNA antibodies.
Significance of combined detection of autoantibodies in systemic lupus erythematosus

苏茵,贾汝琳,栗占国

DOI: https://doi.org/10.3760/j:issn:1007-7480.2005.01.005

2005-01-01

Abstract:Objective To compare the specificity and sensitivity of antibodies against cell membrane associated DNA (cmDNA)、 nucleosome (AnuA)、 double stranded DNA (dsDNA)、 deoxyribonucleoprotein (DNP) and antinuclear antibodies (ANA) in systemic lupus erythematosus (SLE). To analyze the relationship between these auto-antibodies in SLE. Methods One hundred and twenty five SLE patients and 118 other rheumatic diseases patients were studied. The latter included primary Sj?觟gren syndrome, ploymyositis, dermatomyositis, rheumatoid arthritis, osteoarthritis and systemic sclerosis. Indirect immunofluorescence was used to measure the anti-cmDNA antibodies and ANA. The enzyme-linked immunosorbent assay (ELISA) was used to measure the AnuA. Anti-DNP antibodies were detected by latex agglutination text and anti-dsDNA antibodies were detected by colloidal gold-technique. Results The seropositive rates of AnuA、 anti-cmDNA、 DNP、 dsDNA antibodies and ANA were 68%、 38.4%、 51.2%、 49.6% and 95.2% respectively in SLE patients. They were much higher than those of control groups (P0.001). The sensitivities of ANA and AnuA were higher than those of anti-DNP、 cmDNA and dsDNA antibodies in SLE(P0.05). Specificities of AnuA、anti-DNP、 cmDNA and dsDNA antibodies in SLE were higher than that of ANA. Combination of AnuA and anti-DNP antibodies or anti-dsDNA antibodies increased the sensitivity of autoantibodies in the diagnosis of SLE. Conclusion AnuA、 anti-cmDNA、 DNP and dsDNA antibodies are specific antibodies for diagnosis of SLE. Combination of AnuA and anti-DNP or anti-dsDNA antibodies can significantly improve the sensitivity of these autoantibodies in the diagnosis of SLE.
Clinical significance of combined detection of autoantibodies in patients with systemic lupus erythematosus

Yuan-hui YANG,Wei ZHOU,Hong LU,Wen-yue XIE

DOI: https://doi.org/10.3969/j.issn.1672-9455.2014.17.016

2014-01-01

Abstract:Objective To explore the clinical significance of combined detection of autoantibodies in patients with systemic lupus erythematosus (SLE) .Methods A total of 60 SLE patients ,treated in this hospital from Jan . 2012 to Jan .2014 ,were enrolled as SLE group ,and 60 healthy subjects were enrolled as control group .Enzyme-linked immunosorbent assay was performed to detect anti-double stranded DNA (dsDNA ) antibody ,and Western blot was used to detected ant-nucleosome antibody (AnuA) and anti-Sm antibody .Diagnostic performance of single and com-bined detection of antibodies was compared .Results Positive rates of anti-dsDNA antibody ,AnuA ,anti-Sm antibody and combined detection of the three antibodies were 93 .3% ,33 .3% ,46 .7% and 96 .7% in SLE group ,which were significantly higher than control group(P<0 .05) .Combined detection of the three antibodies were with higher diag-nostic performance .Conclusion Combined detection of AnuA ,anti-Sm antibody and anti-dsDNA antibody might be helpful to avoid missed diagnosis of SLE .
Screening epitope peptides based on a phage-displayed random peptide and peptide microarrays to contribute to improving the diagnostic efficiency of systemic lupus erythematosus

Xin Li,Hong-Xia Wang,Xiaofeng Yin,Xueheng Li,Haixia Li,Xiaohe Zhang,Zheng Wang,Yu-Rong Qiu

DOI: https://doi.org/10.1016/j.imlet.2023.05.008

IF: 4.23

2023-05-28

Immunology Letters

Abstract:Background Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases in China. At present, there are hundreds of autoantibodies in SLE patients; however, only a dozen of the autoantibodies can be routinely detected, and the available diagnostic antibodies are not sufficient for diagnosis or differential diagnosis of SLE patients with atypical clinical manifestations or other autoimmune diseases. Therefore, it is necessary to find new diagnostic markers to improve the diagnostic effect of SLE. Methods The displayed random peptide library and peptide microarray were combined to identify SLE-related epitope peptides. A case-control design was used. The IgG antibodies in the sera from SLE patients, healthy controls, and other autoimmune disease controls underwent a reaction with the phage-display random peptide library, respectively. Selected epitope peptides were used to construct a peptide chip. A total of 644 serum samples (including 296 SLE patients, 168 disease controls, and 180 healthy controls) were used for further screening and verification. Peptides with an area under the curve (AUC) > 0.650 were further verified by ELISA. Finally, 500 serum samples (including 200 SLE patients, 150 disease controls, and 150 healthy controls) were used to verify and evaluate the diagnostic and differential diagnostic efficacy of the selected peptides. Results After the previous screening, five epitope peptides (SLE_P19, SLE_P20, SLE_P27, SLE_P28, and SLE_P29) may have potential as SLE diagnostic markers. Additionally, SLE_P27 was superior to the other four peptides in the diagnosis and differential diagnosis of SLE and rheumatoid arthritis (RA). The AUC of SLE_P27 was 0.938, the sensitivity was 76.00%, the specificity was 92.70%, the positive likelihood ratio was 10.411, the negative likelihood ratio was 0.259, and the accuracy was 84.40%. The diagnostic efficacy of SLE can be increased by combining the five selected peptides with the anti-double stranded DNA antibody (anti-dsDNA)and anti-Smith antibodies (anti-Sm). Conclusions In this study, we identified five peptides that may serve as potential biomarkers for SLE diagnosis using the strategy of combining the displayed random peptide library with the peptide microarray. The combination of selected peptides and existing autoantibodies can significantly improve the diagnostic efficiency. These specific peptides are expected to be new diagnostic markers for SLE.

immunology
Determination of specific autoantibodies in patients with systemic lupus erythematosus by Line immunoassay, ELISA and CLIF assay

Kanphai Wongjarit,Niramol Thammacharoenrach,Kanthaporn Dityen,Yadah Kaewopas,Naravadee Kositpesat,Sittichai Ukritchon,Manathip Osiri,Jongkonnee Wongpiyabovorn

DOI: https://doi.org/10.12932/AP-301019-0681

Abstract:Background: Detection of specific antinuclear-antibodies is very importance in term of diagnosis, prognosis and management of patients with systemic lupus erythematosus (SLE). To date, Line immunoassay (LIA), enzyme-linked immunosorbent assay (ELISA) and Crithidia luciliae indirect immunofluorescence (CLIF) assay are commonly used for detection of specific antinuclear-antibodies. Objective: To determine the performance of LIA, ELISA and CLIF for the detection of anti-double-stranded DNA (dsDNA), anti-nucleosome, and anti-extractable nuclear antigens (ENA) antibodies in patients with SLE. Methods: A total 100 sera from 50 patients with SLE, 25 patients with disease control and 25 healthy control subjects were tested for anti-dsDNA, anti-nucleosome, and anti-ENA antibodies by LIA, ELISA, and CLIF assay. Agreement and diagnostic performance of each assay were analyzed using Cohen's kappa coefficient and receiver operating characteristic curve analysis. Results: For the detection of anti-dsDNA antibody, ELISA had a substantial agreement with CLIF assay (? = 0.74) but LIA had a fair agreement with ELISA and CLIF assay (? = 0.37, and 0.35 respectively). For the detection of anti-nucleosome, anti-nRNP/Sm, anti-Sm, anti-SSA, and anti-SSB antibodies, LIA had a substantial to perfect agreement with ELISA (? = 0.64, 0.78, 0.68, 0.91, and 0.74, respectively). Anti-dsDNA-NcX ELISA and anti-dsDNA CLIF assay had equally diagnostic performance (sensitivity, 66% vs. 68%, and specificity, 96% vs. 94%, respectively) whereas, anti-dsDNA LIA has low sensitivity (22%) but high specificity (100%). Conclusions: LIA, ELISA, and CLIF demonstrated comparable performance for the detection of specific antinuclear-antibodies. However, there were some discrepancy between assays particularly in the detection of anti-dsDNA antibody.
A panning DLT procedure for three-dimensional videography.

B. Yu,T. Koh,J. Hay

DOI: https://doi.org/10.1016/0021-9290(93)90036-E

IF: 2.4

1993-06-01

Journal of Biomechanics

Abstract:
A simple and highly efficient method of IFI44L methylation detection for the diagnosis of systemic lupus erythematosus

Bo Zhang,Limin Liu,Tian Zhou,Xiaoli Shi,Haijing Wu,Zhongyuan Xiang,Ming Zhao,Qianjin Lu

DOI: https://doi.org/10.1016/j.clim.2020.108612

IF: 10.19

2020-12-01

Clinical Immunology

Abstract:Systemic lupus erythematosus (SLE) is a complex heterogenous autoimmune disease that can be challenging to diagnose. We previously identified the IFN-induced protein 44-like (IFI44L) methylation marker for SLE diagnosis, which can be detected by pyrosequencing. Although the previous technique has high sensitivity and specificity, it requires special equipment and high cost for detection. Here, we established a high-resolution melting-quantitative polymerase chain reaction (HRM-qPCR) assay to detect the methylation of IFI44L promoter for the diagnosis of SLE. The result was determined according to the standard melting curve of the methylation level of the IFI44L promoter region. The sensitivity was 88.571% and the specificity was 97.087%. The HRM-qPCR and pyrosequencing results presented good consistency when both methods were used to detect the methylation of the IFI44L promoter for SLE diagnosis. Furthermore, the HRM-qPCR method can be used to distinguish SLE from other autoimmune diseases, infectious diseases and virus-related cancers.

immunology

[Role of interleukin-1 in osteoarthritis].

Clinical Performance of Enzyme Linked Immunosorbent Assay Detecting Serum Antibodies Against Double-stranded DNA in Diagnosis of Systemic Lupus Erythematosus

Clinical Evaluation of A New Quantitative Enzyme-Linked Immunosorbent Assay for Anti-Dsdna Antibodies Measured in Patients with Systemic Lupus Erythematosus

Two tests to detect anti-double stranded DNA antibodies in the diagnostic value of systemic lupus erythematosus

An assessment on diagnostic efficacy of different methods in combination for the detection of anti-dsDNA antibody in SLE patients

Comparisons of Anti-dsDNA Antibody Detection Methods by Chemiluminescent Immunoassay and Enzyme-Linked Immunosorbent Assay in Systemic Lupus Erythematosus

Comparative analysis of contemporary anti-double stranded DNA antibody assays for systemic lupus erythematosus

The correlation between the avidity or level of serum anti-dsDNA antibody with SLE disease progression and their influence on the performance of different detection techniques

Anti-Double-Stranded DNA Isotypes and Anti-C1q Antibody Improve the Diagnostic Specificity of Systemic Lupus Erythematosus

Long Non-Coding RNAs in Systemic Lupus Erythematosus: New Insights into Disease Pathogenesis and Diagnosis.

Values of qualitative assays for anti-ds-DNA and anti-nucleosome antibodies in diagnosis of systemic lupus erythematosus

DNA-associated Autoantibodies to Cell Membrane for Rapid Detection of Systemic Lupus Erythematosus

The role of cyclic GMP-AMP synthase and Interferon-I-inducible protein 16 as candidatebiomarkers of systemic lupus erythematosus

Correlation of systemic lupus erythematosus clinical phenotypes with anti-double-stranded DNA antibodies and performance comparison of 4 commercial determination kits

Significance of combined detection of autoantibodies in systemic lupus erythematosus

Clinical significance of combined detection of autoantibodies in patients with systemic lupus erythematosus

Screening epitope peptides based on a phage-displayed random peptide and peptide microarrays to contribute to improving the diagnostic efficiency of systemic lupus erythematosus

Determination of specific autoantibodies in patients with systemic lupus erythematosus by Line immunoassay, ELISA and CLIF assay

A panning DLT procedure for three-dimensional videography.

A simple and highly efficient method of IFI44L methylation detection for the diagnosis of systemic lupus erythematosus